Key result
Dual antiplatelet therapy with aspirin and either clopidogrel or ticagrelor did not significantly influence mean platelet volume or other platelet indices after percutaneous coronary intervention.
Why the study?
Platelet indices correlate with coronary artery disease severity and prognosis, but very few studies have evaluated them under dual antiplatelet therapy after PCI.
Does dual antiplatelet therapy with clopidogrel or ticagrelor influence platelet indices after percutaneous coronary intervention?
Observational (n=719)
No
Does dual antiplatelet therapy with clopidogrel or ticagrelor influence platelet indices after percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
No impact of DAPT on post-PCI platelet indices suggests no routine monitoring; leaves open prognostic value in prospective studies.
Platelet indices have been linked to the severity and prognosis of coronary artery disease, but a very small number of studies assessed them under dual antiplatelet therapy after percutaneous coronary intervention (PCI). The aim of this study was to evaluate changes in mean platelet volume (MPV), platelet distribution width (PDW) and platelet-large cell ratio (P-LCR) in these patients. A number of 437 patients with stable coronary artery disease, 131 patients with non ST segment elevation acute coronary syndrome and 151 patients with ST segment elevation myocardial infarction were included in the study. There was no difference between the three groups regarding platelet indices prior to PCI. Follow-up data was available for 181 patients, at a mean follow-up time of 69 (46-98) days. MPV, PDW and PLC-R were similar to those prior to PCI in all three groups. Regarding the P2Y12 inhibitor, clopidogrel or ticagrelor, there was no difference at follow-up between platelet indices irrespective of the indication for PCI.
No takes yet. Share an insight, caveat, or question.
Şuş et al. (2020) conducted an observational in Coronary artery disease undergoing percutaneous coronary intervention (n=719). P2Y12 inhibitors (Clopidogrel or Ticagrelor) vs. Compared to each other and baseline was evaluated on Changes in mean platelet volume (MPV), platelet distribution width (PDW), and platelet-large cell ratio (P-LCR) at follow-up. Dual antiplatelet therapy with aspirin and either clopidogrel or ticagrelor did not significantly influence mean platelet volume or other platelet indices after percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: